Advertisement

Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study

      Highlights

      • Diabeticstreated with contemporary PCI still had a higher risk of adverse ischemic events compared to non-diabetics
      • The risk of bleeding and stent thrombosis was comparable amongst non-diabetics and diabetics.
      • Long-term ticagrelor monotherapy did not affect the outcomes of diabeticsfollowing percutaneous coronary intervention.

      Abstract

      Background and aims

      Diabetes has been well recognized as a strong predictor for adverse outcomes after percutaneous coronary intervention (PCI), however, studies in the era of drug-eluting stent and potent P2Y12 inhibitors have shown conflicting results. We aimed to assess ischemic and bleeding outcomes after contemporary PCI according to diabetic status.

      Methods

      We studied 15,957 patients undergoing PCI for stable or acute coronary syndrome in the GLOBAL LEADERS study with known baseline diabetic status. The primary endpoint was all-cause death or new Q-wave myocardial infarction at 2 years. The secondary safety endpoint was major bleeding defined as bleeding academic research consortium (BARC) type 3 or 5.

      Results

      A quarter of the study cohort were diabetic (4038/15,957), and these patients had a significantly higher risk of primary endpoint at 2 years compared to non-diabetics (adjusted hazard ratio [HR] 1.38; 95% confidence interval [CI] 1.17–1.63). The difference was driven by a significantly higher risk of all-cause mortality at 2 years in diabetics (adjusted HR 1.47, 95% CI 1.22–1.78). The risk of BARC 3 or 5 bleeding was comparable between the two groups (adjusted HR 1.09, 95% CI 0.86–1.39). The antiplatelet strategy (experimental versus reference strategy) had no significant effect on the rates of primary endpoint and secondary safety endpoint at 2 years in patients with and without diabetes.

      Conclusions

      Diabetic patients had higher risk of ischemic events after PCI than non-diabetic patients, whilst bleeding risk was comparable. The outcomes of diabetic patients following PCI were not affected by the two different antiplatelet strategies.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chatterjee S.
        • Khunti K.
        • Davies M.J.
        Type 2 diabetes.
        Lancet (London, England). 2017; 389: 2239-2251
        • Ingelfinger J.R.
        • Jarcho J.A.
        Increase in the incidence of diabetes and its implications.
        N. Engl. J. Med. 2017; 376: 1473-1474
        • Yang Y.
        • Park G.-M.
        • Han S.
        • Kim Y.-G.
        • Suh J.
        • Park H.W.
        • Won K.-B.
        • Ann S.H.
        • Kim S.-J.
        • Kim D.-W.
        • Park M.-W.
        • Her S.H.
        • Lee S.-G.
        Impact of diabetes mellitus in patients undergoing contemporary percutaneous coronary intervention: results from a Korean nationwide study.
        PLoS One. 2018; 13 (e0208746-e0208746)
        • Pi S.H.
        • Rhee T.M.
        • Lee J.M.
        • Hwang D.
        • Park J.
        • Park T.K.
        • Yang J.H.
        • Song Y.B.
        • Choi J.H.
        • Hahn J.Y.
        • Kim B.J.
        • Kim B.S.
        • Gwon H.C.
        • Choi S.H.
        Outcomes in patients with diabetes mellitus according to insulin treatment after percutaneous coronary intervention in the second-generation drug-eluting stent era.
        Am. J. Cardiol. 2018; 121: 1505-1511
        • Koskinas K.C.
        • Siontis G.C.
        • Piccolo R.
        • Franzone A.
        • Haynes A.
        • Rat-Wirtzler J.
        • Silber S.
        • Serruys P.W.
        • Pilgrim T.
        • Raber L.
        • Heg D.
        • Juni P.
        • Windecker S.
        Impact of diabetic status on outcomes after revascularization with drug-eluting stents in relation to coronary artery disease complexity: patient-level pooled analysis of 6081 patients.
        Circ.Cardiovasc.Interv. 2016; 9e003255
        • Kedhi E.
        • Genereux P.
        • Palmerini T.
        • McAndrew T.C.
        • Parise H.
        • Mehran R.
        • Dangas G.D.
        • Stone G.W.
        Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: analysis from 18 pooled randomized trials.
        J. Am. Coll. Cardiol. 2014; 63: 2111-2118
        • Konigstein M.
        • Ben-Yehuda O.
        • Smits P.C.
        • Love M.P.
        • Banai S.
        • Perlman G.Y.
        • Golomb M.
        • Ozan M.O.
        • Liu M.
        • Leon M.B.
        • Stone G.W.
        • Kandzari D.E.
        Outcomes among diabetic patients undergoing percutaneous coronary intervention with contemporary drug-eluting stents: analysis from the BIONICS randomized trial.
        JACC Cardiovasc. Interv. 2018; 11: 2467-2476
        • Hamilos M.
        • Petousis S.
        • Xanthopoulou I.
        • Goudevenos J.
        • Kanakakis J.
        • Sitafidis G.
        • Vavouranakis M.
        • Skalidis E.
        • Kochiadakis G.
        • Lekakis J.
        • Vardas P.E.
        • Alexopoulos D.
        Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a Greek AntiPlatElet registry substudy.
        Coron. Artery Dis. 2018; 29: 53-59
        • James S.
        • Angiolillo D.J.
        • Cornel J.H.
        • Erlinge D.
        • Husted S.
        • Kontny F.
        • Maya J.
        • Nicolau J.C.
        • Spinar J.
        • Storey R.F.
        • Stevens S.R.
        • Wallentin L.
        Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.
        Eur. Heart J. 2010; 31: 3006-3016
        • Faggioni M.
        • Baber U.
        • Sartori S.
        • Giustino G.
        • Cohen D.J.
        • Henry T.D.
        • Farhan S.
        • Ariti C.
        • Dangas G.
        • Gibson M.
        • Giacoppo D.
        • Krucoff M.W.
        • Aquino M.
        • Chandrasekhar J.
        • Moliterno D.J.
        • Colombo A.
        • Vogel B.
        • Chieffo A.
        • Kini A.S.
        • Witzenbichler B.
        • Weisz G.
        • Steg P.G.
        • Pocock S.
        • Mehran R.
        Incidence, patterns, and associations between dual-antiplatelet therapy cessation and risk for adverse events among patients with and without diabetes mellitus receiving drug-eluting stents: results from the PARIS registry.
        JACC Cardiovasc. Interv. 2017; 10: 645-654
        • Baber U.
        • Mehran R.
        • Giustino G.
        • Cohen D.J.
        • Henry T.D.
        • Sartori S.
        • Ariti C.
        • Litherland C.
        • Dangas G.
        • Gibson C.M.
        • Krucoff M.W.
        • Moliterno D.J.
        • Kirtane A.J.
        • Stone G.W.
        • Colombo A.
        • Chieffo A.
        • Kini A.S.
        • Witzenbichler B.
        • Weisz G.
        • Steg P.G.
        • Pocock S.
        Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS.
        J. Am. Coll. Cardiol. 2016; 67: 2224-2234
        • Costa F.
        • van Klaveren D.
        • James S.
        • Heg D.
        • Raber L.
        • Feres F.
        • Pilgrim T.
        • Hong M.K.
        • Kim H.S.
        • Colombo A.
        • Steg P.G.
        • Zanchin T.
        • Palmerini T.
        • Wallentin L.
        • Bhatt D.L.
        • Stone G.W.
        • Windecker S.
        • Steyerberg E.W.
        • Valgimigli M.
        Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
        Lancet (London, England). 2017; 389: 1025-1034
        • Vranckx P.
        • Valgimigli M.
        • Juni P.
        • Hamm C.
        • Steg P.G.
        • Heg D.
        • van Es G.A.
        • McFadden E.P.
        • Onuma Y.
        • van Meijeren C.
        • Chichareon P.
        • Benit E.
        • Mollmann H.
        • Janssens L.
        • Ferrario M.
        • Moschovitis A.
        • Zurakowski A.
        • Dominici M.
        • Van Geuns R.J.
        • Huber K.
        • Slagboom T.
        • Serruys P.W.
        • Windecker S.
        Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
        Lancet (London, England). 2018; 392: 940-949
        • Mehran R.
        • Rao S.V.
        • Bhatt D.L.
        • Gibson C.M.
        • Caixeta A.
        • Eikelboom J.
        • Kaul S.
        • Wiviott S.D.
        • Menon V.
        • Nikolsky E.
        • Serebruany V.
        • Valgimigli M.
        • Vranckx P.
        • Taggart D.
        • Sabik J.F.
        • Cutlip D.E.
        • Krucoff M.W.
        • Ohman E.M.
        • Steg P.G.
        • White H.
        Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.
        Circulation. 2011; 123: 2736-2747
        • Cutlip D.E.
        • Windecker S.
        • Mehran R.
        • Boam A.
        • Cohen D.J.
        • van Es G.A.
        • Steg P.G.
        • Morel M.A.
        • Mauri L.
        • Vranckx P.
        • McFadden E.
        • Lansky A.
        • Hamon M.
        • Krucoff M.W.
        • Serruys P.W.
        Clinical end points in coronary stent trials: a case for standardized definitions.
        Circulation. 2007; 115: 2344-2351
        • Garcia-Garcia H.M.
        • McFadden E.P.
        • Farb A.
        • Mehran R.
        • Stone G.W.
        • Spertus J.
        • Onuma Y.
        • Morel M.A.
        • van Es G.A.
        • Zuckerman B.
        • Fearon W.F.
        • Taggart D.
        • Kappetein A.P.
        • Krucoff M.W.
        • Vranckx P.
        • Windecker S.
        • Cutlip D.
        • Serruys P.W.
        Standardized end point definitions for coronary intervention trials: the academic research consortium-2 consensus document.
        Circulation. 2018; 137: 2635-2650
        • Pocock S.J.
        • McMurray J.J.V.
        • Collier T.J.
        Statistical controversies in reporting of clinical trials: Part 2 of a 4-Part Series on statistics for clinical trials.
        J. Am. Coll. Cardiol. 2015; 66: 2648-2662
        • Levine G.N.
        • Bates E.R.
        • Bittl J.A.
        • Brindis R.G.
        • Fihn S.D.
        • Fleisher L.A.
        • Granger C.B.
        • Lange R.A.
        • Mack M.J.
        • Mauri L.
        • Mehran R.
        • Mukherjee D.
        • Newby L.K.
        • O'Gara P.T.
        • Sabatine M.S.
        • Smith P.K.
        • Smith S.C.
        ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease.
        A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines 2016. 2016; 68: 1082-1115
        • Levey A.S.
        • Bosch J.P.
        • Lewis J.B.
        • Greene T.
        • Rogers N.
        • Roth D.
        A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.
        Ann. Intern. Med. 1999; 130: 461-470
        • Bonaa K.H.
        • Mannsverk J.
        • Wiseth R.
        • Aaberge L.
        • Myreng Y.
        • Nygard O.
        • Nilsen D.W.
        • Klow N.E.
        • Uchto M.
        • Trovik T.
        • Bendz B.
        • Stavnes S.
        • Bjornerheim R.
        • Larsen A.I.
        • Slette M.
        • Steigen T.
        • Jakobsen O.J.
        • Bleie O.
        • Fossum E.
        • Hanssen T.A.
        • Dahl-Eriksen O.
        • Njolstad I.
        • Rasmussen K.
        • Wilsgaard T.
        • Nordrehaug J.E.
        Drug-eluting or bare-metal stents for coronary artery disease.
        N. Engl. J. Med. 2016; 375: 1242-1252
        • Serruys P.W.
        • Farooq V.
        • Kalesan B.
        • de Vries T.
        • Buszman P.
        • Linke A.
        • Ischinger T.
        • Klauss V.
        • Eberli F.
        • Wijns W.
        • Morice M.C.
        • Di Mario C.
        • Corti R.
        • Antoni D.
        • Sohn H.Y.
        • Eerdmans P.
        • Rademaker-Havinga T.
        • van Es G.A.
        • Meier B.
        • Juni P.
        • Windecker S.
        Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted from A Durable versus ERodable Stent Coating) randomized, noninferiority trial.
        JACC Cardiovasc. Interv. 2013; 6: 777-789
        • Kufner S.
        • Joner M.
        • Thannheimer A.
        • Hoppmann P.
        • Ibrahim T.
        • Mayer K.
        • Cassese S.
        • Laugwitz K.-L.
        • Schunkert H.
        • Kastrati A.
        • Byrne R.A.
        Ten-year clinical outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease.
        Circulation. 2019; 139: 325-333
        • Chichareon P.
        • Katagiri Y.
        • Asano T.
        • Takahashi K.
        • Kogame N.
        • Modolo R.
        • Tenekecioglu E.
        • Chang C.C.
        • Tomaniak M.
        • Kukreja N.
        • Wykrzykowska J.J.
        • Piek J.J.
        • Serruys P.W.
        • Onuma Y.
        Mechanical properties and performances of contemporary drug-eluting stent: focus on the metallic backbone.
        Expert Rev. Med. Devices. 2019; 16: 211-228
        • Escaned J.
        • Collet C.
        • Ryan N.
        • De Maria G.L.
        • Walsh S.
        • Sabate M.
        • Davies J.
        • Lesiak M.
        • Moreno R.
        • Cruz-Gonzalez I.
        • Hoole S.P.
        • Ej West N.
        • Piek J.J.
        • Zaman A.
        • Fath-Ordoubadi F.
        • Stables R.H.
        • Appleby C.
        • van Mieghem N.
        • van Geuns R.J.
        • Uren N.
        • Zueco J.
        • Buszman P.
        • Iniguez A.
        • Goicolea J.
        • Hildick-Smith D.
        • Ochala A.
        • Dudek D.
        • Hanratty C.
        • Cavalcante R.
        • Kappetein A.P.
        • Taggart D.P.
        • van Es G.A.
        • Morel M.A.
        • de Vries T.
        • Onuma Y.
        • Farooq V.
        • Serruys P.W.
        • Banning A.P.
        Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study.
        Eur. Heart J. 2017; 38: 3124-3134
        • Serruys P.W.
        • Kogame N.
        • Katagiri Y.
        • Modolo R.
        • Buszman P.E.
        • Iniguez-Romo A.
        • Goicolea J.
        • Hildick-Smith D.
        • Ochala A.
        • Dudek D.
        • Piek J.J.
        • Wykrzykowska J.J.
        • Escaned J.
        • Banning A.P.
        • Farooq V.
        • Onuma Y.
        Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with three-vessel disease: 2-year follow-up of the SYNTAX II study.
        EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2019; 15: e244-e252
        • Dangas G.D.
        • Claessen B.E.
        • Mehran R.
        • Xu K.
        • Fahy M.
        • Parise H.
        • Henriques J.P.
        • Ohman E.M.
        • White H.D.
        • Stone G.W.
        Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes.
        JACC Cardiovasc. Interv. 2012; 5: 1097-1105
        • Gori T.
        • Polimeni A.
        • Indolfi C.
        • Räber L.
        • Adriaenssens T.
        • Münzel T.
        Predictors of stent thrombosis and their implications for clinical practice.
        Nat. Rev. Cardiol. 2019; 16: 243-256
        • Iakovou I.
        • Schmidt T.
        • Bonizzoni E.
        • Ge L.
        • Sangiorgi G.M.
        • Stankovic G.
        • Airoldi F.
        • Chieffo A.
        • Montorfano M.
        • Carlino M.
        • Michev I.
        • Corvaja N.
        • Briguori C.
        • Gerckens U.
        • Grube E.
        • Colombo A.
        Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.
        Jama. 2005; 293: 2126-2130
        • Gargiulo G.
        • Windecker S.
        • da Costa B.R.
        • Feres F.
        • Hong M.K.
        • Gilard M.
        • Kim H.S.
        • Colombo A.
        • Bhatt D.L.
        • Kim B.K.
        • Morice M.C.
        • Park K.W.
        • Chieffo A.
        • Palmerini T.
        • Stone G.W.
        • Valgimigli M.
        Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials.
        BMJ (Clinical research ed). 2016; 355: i5483
        • Ferreiro J.L.
        • Angiolillo D.J.
        Diabetes and antiplatelet therapy in acute coronary syndrome.
        Circulation. 2011; 123: 798-813
        • Ferroni P.
        • Basili S.
        • Falco A.
        • Davi G.
        Platelet activation in type 2 diabetes mellitus.
        J. Thromb. Haemost. : JTH. 2004; 2: 1282-1291
        • Angiolillo D.J.
        • Bernardo E.
        • Sabate M.
        • Jimenez-Quevedo P.
        • Costa M.A.
        • Palazuelos J.
        • Hernandez-Antolin R.
        • Moreno R.
        • Escaned J.
        • Alfonso F.
        • Banuelos C.
        • Guzman L.A.
        • Bass T.A.
        • Macaya C.
        • Fernandez-Ortiz A.
        Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
        J. Am. Coll. Cardiol. 2007; 50: 1541-1547
        • Patti G.
        • Cavallari I.
        • Andreotti F.
        • Calabro P.
        • Cirillo P.
        • Denas G.
        • Galli M.
        • Golia E.
        • Maddaloni E.
        • Marcucci R.
        • Parato V.M.
        • Pengo V.
        • Prisco D.
        • Ricottini E.
        • Renda G.
        • Santilli F.
        • Simeone P.
        • De Caterina R.
        Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs.
        Nat. Rev. Cardiol. 2019; 16: 113-130
        • Grodzinsky A.
        • Arnold S.V.
        • Wang T.Y.
        • Sharma P.
        • Gosch K.
        • Jones P.G.
        • Bhatt D.L.
        • Steg P.G.
        • McGuire D.K.
        • Cohen D.J.
        • Spertus J.A.
        • Chhatriwalla A.K.
        • Lind M.
        • Graham G.
        • Kosiborod M.
        Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy.
        Am. Heart J. 2016; 182: 111-118
        • Rivas Rios J.R.
        • Franchi F.
        • Rollini F.
        • Angiolillo D.J.
        Diabetes and antiplatelet therapy: from bench to bedside.
        Cardiovasc. Diagn. Ther. 2018; 8: 594-609
        • Head S.J.
        • Kaul S.
        • Tijssen J.G.P.
        • Serruys P.W.
        • Kappetein A.P.
        Subgroup Analyses in trial reports comparing percutaneous coronary intervention with coronary artery bypass SurgerySubgroup Analyses in trials of PCI vs CABGLetters.
        J. Am. Med. Assoc. 2013; 310: 2097-2098